EA6174 – Pembrolizumab Compared to Standard of Care Observation in Treating Patients With Completely Resected Stage I-III Merkel Cell Cancer

Physician and Research Staff Educational Materials:

These materials are intended for promotional use among health care professionals and are NOT intended for use as patient educational materials.

  • Physician Fact Sheet: schema, study objectives, eligibility criteria, and other key information about the study.

Patient Educational Materials:

Participating sites should note that the Central Institutional Review Board (CIRB) has approved this material, which can be downloaded from the Cancer Trials Support Unit website (www.ctsu.org). The material is located under the EA6174 Protocol; click on the CIRB Documents tab, and then Amendment Reviews. For sites utilizing local IRBs, please submit this in accordance with your local IRB policies prior to use.

  • Patient Frequently Asked Questions: Frequently asked question handout about treatment, eligibility criteria, and potential enrollment issues with answers in lay language.

Additional Information on Cancer.gov: Displayed below is an interactive view of the study record as it appears in the government registry. If you are experiencing technical difficulties with this view, visit clinicaltrials.gov and search for record NCT03712605.